Bavarian Nordic A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bavarian Nordic A/S
ASCO 2023 – Bicara Eyes Head And Neck Niche
Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.
10 Approvals To Look Out For In Q2
The second quarter has already seen the approval of Gamida Cell’s cell therapy Omisirge, and with the help of Biomedtracker, Scrip highlights 10 of the more interesting new drug approvals due in the next three months.
Bavarian Nordic Comes Up On The Rails In RSV Race
GSK and Pfizer are both likely to get FDA approval for their respiratory syncytial virus products shortly but Bavarian Nordic is progressing well with its differentiated five RSV-specific antigen jab.
Mpox And Newfound ‘Punching Power’ Are Bringing Bavarian Nordic Closer To $1bn Target
Bavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.